Latest news
Analytical Characterization Supports Confidence in Monoclonal Antibody Biosimilars - Center for BiosimilarsCenter for Biosimilars · Thu, 06 Aug 2026 13:05:04 GMTFDA Approves Rituximab Biosimilar Commercialized in US by Fresenius Kabi - Contract PharmaContract Pharma · Tue, 04 Aug 2026 18:43:31 GMTFresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market - BioSpaceBioSpace · Tue, 04 Aug 2026 02:33:04 GMTDr. Reddy's Laboratories Receives US FDA Approval For Rituximab Biosimilar - SahiSahi · Mon, 03 Aug 2026 01:19:52 GMTUSFDA Approves Dr Reddy's Rituximab Biosimilar for US Market - Medical DialoguesMedical Dialogues · Sat, 01 Aug 2026 07:00:00 GMTPolpharma and Fresenius Kabi's Vedolizumab Biosimilar PB016 Clears FDA, EMA Review Acceptance - BioPharm InternationalBioPharm International · Fri, 31 Jul 2026 16:17:12 GMTDenosumab Biosimilar KN012 Matches Reference Drug in Phase 3 Osteoporosis Trial - Center for BiosimilarsCenter for Biosimilars · Thu, 30 Jul 2026 07:00:00 GMTOpdivo biosimilars one step closer to market entry as EPO revokes BMS patent - JUVE PatentJUVE Patent · Wed, 29 Jul 2026 07:00:00 GMT